{"id":"W4412820579","doi":"10.1038/s41408-025-01329-2","title":"Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"Pharmacyclics; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Swedish Orphan Biovitrum; Sanofi; Kyowa Hakko Kirin; Cilag; Italfarmaco; Seagen; Celltrion; Pfizer; Incyte; BeiGene; Astex Pharmaceuticals; Kite Pharma; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Takeda Pharmaceuticals U.S.A.; Leukemia and Lymphoma Society; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen","keywords":"Brentuximab vedotin; Oncology; Medicine; Internal medicine; Chemotherapy; Subgroup analysis; Anaplastic large-cell lymphoma; Lymphoma; Front line; Clinical trial; Hodgkin lymphoma; Meta-analysis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002564011,0.0002400612,0.0008840117,0.0001962687,0.0002061197,0.00002204936,0.0002202683,0.00007010104,0.00009985446],"category_scores_gemma":[0.00001892235,0.0001239101,0.0008276845,0.0005449926,0.00004592731,0.00002412309,0.00003689545,0.0000531153,0.000001219139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001076179,"about_ca_system_score_gemma":0.0005634603,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005925732,"about_ca_topic_score_gemma":0.001868905,"domain_scores_codex":[0.9983424,0.00008950158,0.000620366,0.0002590303,0.0003909283,0.0002977801],"domain_scores_gemma":[0.9984595,0.0002974949,0.0004796796,0.0005000063,0.000184061,0.00007932648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003503049,0.02282036,0.9132369,0.0002314208,0.03667149,0.0000486221,0.005460597,0.0005913805,0.001232476,0.00001911894,0.001265061,0.01491955],"study_design_scores_gemma":[0.1542491,0.003766072,0.7564871,0.000515225,0.05612423,0.00005234422,0.002044633,0.002112469,0.0227202,0.000009803382,0.001732714,0.0001861446],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9744626,0.0228774,0.0001301809,0.000328587,0.0006444952,0.001318187,0.0001871064,0.000008845018,0.000042602],"genre_scores_gemma":[0.9940193,0.003791101,0.00003773532,0.000107693,0.0001436285,0.0002535743,0.00001061169,0.00002121988,0.001615154],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1567498,"threshold_uncertainty_score":0.5052909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01372082772655073,"score_gpt":0.2857180315438789,"score_spread":0.2719972038173281,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}